About Abrexa Pharmaceuticals
Abrexa Pharmaceuticals is a private company based in San Diego, California. It has reported $40,133,044 raised in three offerings on Form D since September 2011. Its chief executive is J. Villafranca.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 10, 2025 | Apr 28, 2025 | $22,999,999fully sold | 2 | $11.4M | EquityRule 506(b) | Form D ↗ |
| Jul 25, 2018 | Aug 8, 2018amended Feb 7, 2019 | $16,632,252fully sold | 7 | $2.3M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Aug 25, 2011 | Sep 6, 2011 | $500,793fully sold | 11 | $45,527 | Equity, Debt, Options, Securities on exercise06 | Form D ↗ |
| Total, three offerings | $40,133,044 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Abrexa Pharmaceuticals's Form D filed Apr 28, 2025.
Earlier filings also listed David Hugley (director, last listed Feb 2019), Nicole Vitullo (director, last listed Sep 2011), Lynne Rollins (executive officer, last listed Sep 2011) and Eckard Weber, M.D. (president and chief executive officer, director, last listed Sep 2011).